Dementia - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 202
   

Global Markets Direct’s, ‘Dementia Pipeline Review, H2 2015’, provides an overview of the Dementia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Dementia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dementia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Dementia - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dementia Overview 9
Therapeutics Development 10
Pipeline Products for Dementia - Overview 10
Pipeline Products for Dementia - Comparative Analysis 11
Dementia - Therapeutics under Development by Companies 12
Dementia - Therapeutics under Investigation by Universities/Institutes 16
Dementia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dementia - Products under Development by Companies 21
Dementia - Products under Investigation by Universities/Institutes 25
Dementia - Companies Involved in Therapeutics Development 26
Adamas Pharmaceuticals, Inc. 26
Addex Therapeutics Ltd 27
Alector LLC 28
AlzProtect SAS 29
Apceth GmbH & Co. KG 30
BioArctic Neuroscience AB 31
Biogen, Inc. 32
Biotie Therapies Corp. 33
Chase Pharmaceuticals Corporation 34
Chronos Therapeutics Limited 35
Daewoong Pharmaceutical Co., Ltd. 36
Eisai Co., Ltd. 37
FORUM Pharmaceuticals Inc. 38
H. Lundbeck A/S 39
Hyundai Pharmaceutical Co., Ltd. 40
Ildong Pharmaceutical Co., Ltd. 41
IMMD Inc. 42
ImStar Therapeutics Inc. 43
Integrative Research Laboratories Sweden AB 44
Intellect Neurosciences, Inc. 45
Intra-Cellular Therapies, Inc. 46
MediPost Co., Ltd. 47
Neurimmune Holding AG 48
Neurodyn Inc. 49
Neuropore Therapies, Inc. 50
Oryzon Genomics S.A. 51
Otsuka Holdings Co., Ltd. 52
Pacific Northwest Biotechnology, LLC 53
Pivot Pharmaceuticals Inc 54
ProteoTech, Inc. 55
Sinil Pharmaceutical Co., Ltd 56
SK Chemicals Co., Ltd. 57
Stelic Institute & Co. 58
Sumitomo Dainippon Pharma Co., Ltd. 59
Sylentis S.A. 60
TauRx Therapeutics Ltd. 61
Tautatis Incorporated 62
Varinel, Inc. 63
WhanIn Pharmaceutical Co., Ltd. 64
Dementia - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 70
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
(memantine hydrochloride ER + donepezil hydrochloride) - Drug Profile 77
Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile 78
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 79
APC-621 - Drug Profile 80
aripiprazole - Drug Profile 81
AVCRI-104P3 - Drug Profile 83
AZP-2006 - Drug Profile 84
BAN-0805 - Drug Profile 86
brexpiprazole - Drug Profile 87
CB-2233 - Drug Profile 90
CB-8411 - Drug Profile 91
choline alfoscerate SR - Drug Profile 92
CPC-201 - Drug Profile 93
CPC-252 - Drug Profile 94
D-217 - Drug Profile 95
dehydroevodiamine hydrochloride - Drug Profile 96
dipraglurant IR - Drug Profile 97
Drugs for Dementia - Drug Profile 98
Drugs to Agonize c-MET for Dementia - Drug Profile 99
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 100
DWJ-1365 - Drug Profile 101
E-2609 - Drug Profile 102
encenicline hydrochloride - Drug Profile 103
FRM-0334 - Drug Profile 106
GIBH-130 - Drug Profile 108
Gln-1062 - Drug Profile 109
GTC-6000 - Drug Profile 111
gugulipid - Drug Profile 112
HOB-075 - Drug Profile 113
IIPP-1 - Drug Profile 114
IMD-4482 - Drug Profile 115
IRL-752 - Drug Profile 116
ITI-007 - Drug Profile 117
KR-12 - Drug Profile 119
LUAF-20513 - Drug Profile 120
MM-201 - Drug Profile 121
Monoclonal Antibodies for Dementia and Alzheimer''s Disease - Drug Profile 122
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 123
NAT - Drug Profile 124
Neurostem - Drug Profile 125
NI-205 - Drug Profile 127
NI-308 - Drug Profile 128
NNC-269100 - Drug Profile 129
OG-635 - Drug Profile 130
OV-201 - Drug Profile 131
P-003 - Drug Profile 132
PD-61W3 - Drug Profile 133
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 134
PST-900 - Drug Profile 135
RDC-5 - Drug Profile 136
SID-111 - Drug Profile 138
SIN-1502 - Drug Profile 139
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 140
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 141
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 142
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 143
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer''s Disease - Drug Profile 144
SYN-120 - Drug Profile 145
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 146
TAK-070 - Drug Profile 147
TauC-3 - Drug Profile 148
TPI-287 - Drug Profile 149
TRx-0237 - Drug Profile 151
TTT-3002 - Drug Profile 153
VAR-10100 - Drug Profile 154
WIB-1001C - Drug Profile 155
zonisamide - Drug Profile 156
Dementia - Recent Pipeline Updates 157
Dementia - Dormant Projects 183
Dementia - Discontinued Products 187
Dementia - Product Development Milestones 188
Featured News & Press Releases 188
Appendix 196
Methodology 196
Coverage 196
Secondary Research 196
Primary Research 196
Expert Panel Validation 196
Contact Us 196
Disclaimer 197

List of Tables

Number of Products under Development for Dementia, H2 2015 15
Number of Products under Development for Dementia - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 18
Number of Products under Development by Companies, H2 2015 (Contd..1) 19
Number of Products under Development by Companies, H2 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2015 21
Comparative Analysis by Late Stage Development, H2 2015 22
Comparative Analysis by Clinical Stage Development, H2 2015 23
Comparative Analysis by Early Stage Development, H2 2015 24
Comparative Analysis by Unknown Stage Development, H2 2015 25
Products under Development by Companies, H2 2015 26
Products under Development by Companies, H2 2015 (Contd..1) 27
Products under Development by Companies, H2 2015 (Contd..2) 28
Products under Development by Companies, H2 2015 (Contd..3) 29
Products under Investigation by Universities/Institutes, H2 2015 30
Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015 31
Dementia - Pipeline by Addex Therapeutics Ltd, H2 2015 32
Dementia - Pipeline by Alector LLC, H2 2015 33
Dementia - Pipeline by AlzProtect SAS, H2 2015 34
Dementia - Pipeline by Apceth GmbH & Co. KG, H2 2015 35
Dementia - Pipeline by BioArctic Neuroscience AB, H2 2015 36
Dementia - Pipeline by Biogen, Inc., H2 2015 37
Dementia - Pipeline by Biotie Therapies Corp., H2 2015 38
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2015 39
Dementia - Pipeline by Chronos Therapeutics Limited, H2 2015 40
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 41
Dementia - Pipeline by Eisai Co., Ltd., H2 2015 42
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2015 43
Dementia - Pipeline by H. Lundbeck A/S, H2 2015 44
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 45
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015 46
Dementia - Pipeline by IMMD Inc., H2 2015 47
Dementia - Pipeline by ImStar Therapeutics Inc., H2 2015 48
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015 49
Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2015 50
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 51
Dementia - Pipeline by MediPost Co., Ltd., H2 2015 52
Dementia - Pipeline by Neurimmune Holding AG, H2 2015 53
Dementia - Pipeline by Neurodyn Inc., H2 2015 54
Dementia - Pipeline by Neuropore Therapies, Inc., H2 2015 55
Dementia - Pipeline by Oryzon Genomics S.A., H2 2015 56
Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 57
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015 58
Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2015 59
Dementia - Pipeline by ProteoTech, Inc., H2 2015 60
Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2015 61
Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2015 62
Dementia - Pipeline by Stelic Institute & Co., H2 2015 63
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 64
Dementia - Pipeline by Sylentis S.A., H2 2015 65
Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2015 66
Dementia - Pipeline by Tautatis Incorporated, H2 2015 67
Dementia - Pipeline by Varinel, Inc., H2 2015 68
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2015 69
Assessment by Monotherapy Products, H2 2015 70
Assessment by Combination Products, H2 2015 71
Number of Products by Stage and Target, H2 2015 73
Number of Products by Stage and Mechanism of Action, H2 2015 76
Number of Products by Stage and Route of Administration, H2 2015 79
Number of Products by Stage and Molecule Type, H2 2015 81
Dementia Therapeutics - Recent Pipeline Updates, H2 2015 162
Dementia - Dormant Projects, H2 2015 188
Dementia - Dormant Projects (Contd..1), H2 2015 189
Dementia - Dormant Projects (Contd..2), H2 2015 190
Dementia - Dormant Projects (Contd..3), H2 2015 191
Dementia - Discontinued Products, H2 2015 192

List of Figures

Number of Products under Development for Dementia, H2 2015 15
Number of Products under Development for Dementia - Comparative Analysis, H2 2015 16
Number of Products under Development by Companies, H2 2015 17
Number of Products under Investigation by Universities/Institutes, H2 2015 21
Comparative Analysis by Clinical Stage Development, H2 2015 23
Comparative Analysis by Early Stage Products, H2 2015 24
Assessment by Monotherapy Products, H2 2015 70
Number of Products by Top 10 Targets, H2 2015 72
Number of Products by Stage and Top 10 Targets, H2 2015 72
Number of Products by Top 10 Mechanism of Actions, H2 2015 75
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 75
Number of Products by Top 10 Routes of Administration, H2 2015 78
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 78
Number of Products by Top 10 Molecule Types, H2 2015 80
Number of Products by Stage and Top 10 Molecule Types, H2 2015 80

Published By: Global Markets Direct
Product Code: Global Markets Direct13294


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: